Literature DB >> 35420374

Standardized reporting of adverse events and functional status from the first 5 years of awake surgery for gliomas: a population-based single-institution consecutive series.

Margret Jensdottir1, Stanislav Beniaminov2, Asgeir S Jakola3, Oscar Persson4, Fritjof Norrelgen5, Sofia Hylin2, Alexander Fletcher-Sandersjöö4, Jiri Bartek4,6.   

Abstract

OBJECTIVE: To report our experience and investigate frequencies of adverse events and functional status from the first 5 years of performing awake surgery for gliomas in a single-center population-based setting.
METHODS: We conducted a review of all patients with a glioma treated with awake surgery during the first 5 years following introduction of awake surgery at our center (February 2015 to February 2020). We assessed functional and radiological outcome, with adverse events classified according to the Landriel-Ibanez classification for neurosurgical complications, while neurological deficits were further subdivided into transient vs permanent. We sought to analyze our initial results and learning curve, as well as compare our results with literature.
RESULTS: Forty-two patients were included. The median age was 38 years (range 18-66) and 13 (31%) were female. The indication for awake surgery was a presumed glioma in or near an eloquent area. The overall 30-day complication rate was 25 (59%), with 19 (45%) grade I complications, 3 (7%) grade II complications, and 3 (7%) grade III complications. Fifteen patients (36%) experienced transient neurological deficits, and 11 (26%) permanent neurological deficits. At 3-month follow-up, the Karnofsky Performance Score was 80 or higher for the entire cohort. The median extent of resection was 87%, with GTR achieved in 11 (26%). In search of potential learning curve difficulties, patients were divided into the 21 patients treated first (Early Group) versus the remaining 21 patients treated later (Late Group); no statistically significant difference in operating time, amount of tumor removed, or incidence of long-term postoperative neurological deficit was identified between groups. No awake surgery was aborted due to seizures. Comparison to the literature was limited by the diverse and unsystematic way in which previous studies have reported adverse events after awake craniotomy for gliomas.
CONCLUSION: We provide a standardized report of adverse events and functional status following awake surgery for glioma during a single-center 5-year learning period, with similar rates of severe adverse events and functional outcome compared to literature without concerns of substantial learning curve difficulties. However, this comparison was flawed by non-standardized reporting of complications, highlighting a demand for more standardized reporting of adverse events after awake craniotomies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Awake surgery; Complications; Functional status; Landriel-Ibanez classification; Learning curve; Neurosurgery

Mesh:

Year:  2022        PMID: 35420374     DOI: 10.1007/s00701-022-05191-0

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.816


  54 in total

1.  Intraoperative subcortical language tract mapping guides surgical removal of gliomas involving speech areas.

Authors:  Lorenzo Bello; Marcello Gallucci; Marica Fava; Giorgio Carrabba; Carlo Giussani; Francesco Acerbi; Pietro Baratta; Valeria Songa; Valeria Conte; Vincenzo Branca; Nino Stocchetti; Costanza Papagno; Sergio Maria Gaini
Journal:  Neurosurgery       Date:  2007-01       Impact factor: 4.654

2.  Complications of first craniotomy for intra-axial brain tumour.

Authors:  A M Cabantog; M Bernstein
Journal:  Can J Neurol Sci       Date:  1994-08       Impact factor: 2.104

3.  Factors influencing surgical complications of intra-axial brain tumours.

Authors:  M Brell; J Ibáñez; L Caral; E Ferrer
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

4.  Post operative supplementary motor area syndrome: clinical features and outcome.

Authors:  U Bannur; V Rajshekhar
Journal:  Br J Neurosurg       Date:  2000-06       Impact factor: 1.596

5.  Post-surgical effects on language in patients with presumed low-grade glioma.

Authors:  M Antonsson; A Jakola; F Longoni; L Carstam; L Hartelius; M Thordstein; M Tisell
Journal:  Acta Neurol Scand       Date:  2017-12-18       Impact factor: 3.209

6.  Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis.

Authors:  Philip C De Witt Hamer; Santiago Gil Robles; Aeilko H Zwinderman; Hugues Duffau; Mitchel S Berger
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Standardized reporting of adverse events after microvascular decompression of cranial nerves; a population-based single-institution consecutive series.

Authors:  Jiri Bartek; Sasha Gulati; Geirmund Unsgård; Clemens Weber; Petter Förander; Ole Solheim; Asgeir S Jakola
Journal:  Acta Neurochir (Wien)       Date:  2016-06-04       Impact factor: 2.216

8.  Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project.

Authors:  Susan M Chang; Ian F Parney; Michael McDermott; Fred G Barker; Meic H Schmidt; Wei Huang; Edward R Laws; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew E Sloan; Mitchel Berger
Journal:  J Neurosurg       Date:  2003-06       Impact factor: 5.115

9.  Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

Authors:  Edward F Chang; Justin S Smith; Susan M Chang; Kathleen R Lamborn; Michael D Prados; Nicholas Butowski; Nicholas M Barbaro; Andrew T Parsa; Mitchel S Berger; Michael M McDermott
Journal:  J Neurosurg       Date:  2008-11       Impact factor: 5.115

10.  Resection probability maps for quality assessment of glioma surgery without brain location bias.

Authors:  Philip C De Witt Hamer; Eef J Hendriks; Emmanuel Mandonnet; Frederik Barkhof; Aeilko H Zwinderman; Hugues Duffau
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.